ES2187756T3 - Uso de una composicion farmaceutica que comprende un peptido supresor del apetito. - Google Patents

Uso de una composicion farmaceutica que comprende un peptido supresor del apetito.

Info

Publication number
ES2187756T3
ES2187756T3 ES97905000T ES97905000T ES2187756T3 ES 2187756 T3 ES2187756 T3 ES 2187756T3 ES 97905000 T ES97905000 T ES 97905000T ES 97905000 T ES97905000 T ES 97905000T ES 2187756 T3 ES2187756 T3 ES 2187756T3
Authority
ES
Spain
Prior art keywords
appetizer
pharmaceutical composition
peptide
suppressing peptide
suppressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97905000T
Other languages
English (en)
Inventor
Lars Thim
Birgitte Schjellerup Wulff
Martin Edward Judge
Ole Dragsbak Madsen
Jens Juul Holst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2187756(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2187756T3 publication Critical patent/ES2187756T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PEPTIDO DE SUPRESION DEL APETITO O FRACCION QUE CONTIENE UN PEPTIDO SUPRESOR DEL APETITO PARA EL TRATAMIENTO DE LA OBESIDAD O DE LA DIABETES TIPO II.
ES97905000T 1996-03-01 1997-02-27 Uso de una composicion farmaceutica que comprende un peptido supresor del apetito. Expired - Lifetime ES2187756T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK23096 1996-03-01
DK23196 1996-03-01

Publications (1)

Publication Number Publication Date
ES2187756T3 true ES2187756T3 (es) 2003-06-16

Family

ID=26063575

Family Applications (3)

Application Number Title Priority Date Filing Date
ES97905000T Expired - Lifetime ES2187756T3 (es) 1996-03-01 1997-02-27 Uso de una composicion farmaceutica que comprende un peptido supresor del apetito.
ES08103786T Expired - Lifetime ES2364705T3 (es) 1996-03-01 1997-02-27 Péptido supresor del apetito, su composición y uso.
ES01122701T Expired - Lifetime ES2306685T3 (es) 1996-03-01 1997-02-27 Peptido supresor del apetito, su composicion y uso.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES08103786T Expired - Lifetime ES2364705T3 (es) 1996-03-01 1997-02-27 Péptido supresor del apetito, su composición y uso.
ES01122701T Expired - Lifetime ES2306685T3 (es) 1996-03-01 1997-02-27 Peptido supresor del apetito, su composicion y uso.

Country Status (22)

Country Link
EP (4) EP2295453A3 (es)
JP (1) JP4064460B2 (es)
KR (1) KR100611130B1 (es)
CN (1) CN1112367C (es)
AT (3) ATE227737T1 (es)
AU (1) AU710818B2 (es)
BR (1) BR9707807A (es)
CA (1) CA2246733C (es)
CY (2) CY2619B2 (es)
CZ (1) CZ297338B6 (es)
DE (3) DE69717092T2 (es)
DK (2) DK1975177T3 (es)
ES (3) ES2187756T3 (es)
FR (1) FR13C0009I2 (es)
HU (1) HU229234B1 (es)
IL (1) IL125805A0 (es)
NO (2) NO323043B1 (es)
PL (1) PL187095B1 (es)
PT (1) PT1975177E (es)
RU (1) RU2197261C2 (es)
UA (1) UA70283C2 (es)
WO (1) WO1997031943A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
UA70283C2 (en) * 1996-03-01 2004-10-15 Novo Nordisk As Peptide (variants), a pharmaceutical composition cpeptide (variants), a pharmaceutical composition composed of peptide and a method for the preparatioomposed of peptide and a method for the preparation thereof (variants) n thereof (variants)
WO1997039031A1 (en) 1996-04-12 1997-10-23 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU4863797A (en) * 1996-11-12 1998-06-03 Novo Nordisk A/S Use of glp-1 peptides
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
DE59811840D1 (de) * 1997-09-12 2004-09-23 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002504527A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
DE69942307D1 (de) * 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6770620B2 (en) 2000-09-18 2004-08-03 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
AU2002224124A1 (en) 2000-12-01 2002-06-11 Takeda Chemical Industries Ltd. Method for producing preparation containing bioactive substance
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
WO2004069314A1 (en) 2003-02-04 2004-08-19 Novo Nordisk A/S Injection device with rotatable dose setting
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
CN1909930B (zh) 2004-01-21 2015-12-16 诺和诺德医疗保健公司 转谷氨酰胺酶介导的肽的接合
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
MXPA06011924A (es) 2004-04-15 2007-06-11 Alkermes Inc Dispositivo de liberacion continua base polimeros.
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5405105B2 (ja) 2005-05-04 2014-02-05 ジーランド ファーマ アクティーゼルスカブ グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ
EP1767545B1 (en) 2005-09-22 2009-11-11 Biocompatibles UK Limited GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US8642727B2 (en) 2006-11-08 2014-02-04 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
CN105688191A (zh) 2007-04-23 2016-06-22 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
AU2008286706B2 (en) * 2007-08-16 2014-03-06 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
US8298561B2 (en) 2009-09-28 2012-10-30 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR20150006052A (ko) 2012-05-03 2015-01-15 질랜드 파마 에이/에스 글루카곤-유사 펩타이드-2 (ｇｌｐ-2) 유사체
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
SG10201911851VA (en) 2016-12-09 2020-02-27 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US20220204553A1 (en) * 2019-05-06 2022-06-30 The University Of Sydney Methods for the fractionation of proteins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
WO1984004330A1 (en) 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
JP2523562B2 (ja) 1985-10-25 1996-08-14 ザイモジェネティックス インコーポレーテッド 外来タンパク質を分泌することを目的としたｂａｒ１の使用法
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
DE3856247T2 (de) 1987-07-24 1999-04-29 Chiron Corp., Emeryville, Calif. Züchtung von insektenzellen mit airlift-reaktoren
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
WO1990005783A1 (en) 1988-11-18 1990-05-31 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
UA70283C2 (en) * 1996-03-01 2004-10-15 Novo Nordisk As Peptide (variants), a pharmaceutical composition cpeptide (variants), a pharmaceutical composition composed of peptide and a method for the preparatioomposed of peptide and a method for the preparation thereof (variants) n thereof (variants)

Also Published As

Publication number Publication date
UA70283C2 (en) 2004-10-15
FR13C0009I2 (fr) 2013-08-16
EP2295453A2 (en) 2011-03-16
CY2619B2 (es) 2013-03-13
RU2197261C2 (ru) 2003-01-27
IL125805A0 (en) 1999-04-11
ES2306685T3 (es) 2008-11-16
CA2246733A1 (en) 1997-09-04
KR100611130B1 (ko) 2006-11-30
EP1975177B1 (en) 2011-04-13
DK0891378T3 (da) 2003-01-06
CA2246733C (en) 2010-07-20
NO2013006I2 (es) 2013-03-12
EP2295453A3 (en) 2011-03-30
PL328732A1 (en) 1999-02-15
DE69740176D1 (de) 2011-05-26
AU1871597A (en) 1997-09-16
KR19990087439A (ko) 1999-12-27
CZ297338B6 (cs) 2006-11-15
EP0891378A1 (en) 1999-01-20
WO1997031943A1 (en) 1997-09-04
EP0891378B1 (en) 2002-11-13
BR9707807A (pt) 1999-07-27
NO2013006I1 (no) 2013-04-02
NO323043B1 (no) 2006-12-27
HUP9902670A3 (en) 2000-02-28
CY2013008I2 (el) 2015-08-05
CN1112367C (zh) 2003-06-25
PL187095B1 (pl) 2004-05-31
DE69738695D1 (de) 2008-06-26
DE69717092T2 (de) 2003-07-24
EP1231218A2 (en) 2002-08-14
CZ273698A3 (cs) 1998-12-16
CY2013008I1 (el) 2015-08-05
ES2364705T3 (es) 2011-09-12
FR13C0009I1 (es) 2013-03-22
NO984005D0 (no) 1998-08-31
NO984005L (no) 1998-08-31
EP1975177A1 (en) 2008-10-01
DE69717092D1 (de) 2002-12-19
JP2000505460A (ja) 2000-05-09
CN1215405A (zh) 1999-04-28
EP1231218B1 (en) 2008-05-14
PT1975177E (pt) 2011-07-26
DK1975177T3 (da) 2011-07-25
ATE395359T1 (de) 2008-05-15
AU710818B2 (en) 1999-09-30
ATE505485T1 (de) 2011-04-15
EP1231218A3 (en) 2002-10-30
HU229234B1 (en) 2013-09-30
ATE227737T1 (de) 2002-11-15
JP4064460B2 (ja) 2008-03-19

Similar Documents

Publication Publication Date Title
ES2187756T3 (es) Uso de una composicion farmaceutica que comprende un peptido supresor del apetito.
DK0946191T3 (da) Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme
ES2184127T3 (es) Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
PT1171465E (pt) Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
MX9206306A (es) Peptidos, procedimiento para su produccion y composicion farmaceutica que los contiene.
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
PT1328269E (pt) Associacao de um antagonista do receptor cb1 e de sibutramina composicoes farmaceuticas que os contem e sua utilizacao para o tratamento da obesidade
TW257672B (es)
PT741716E (pt) Analogos de delta 12,13-iso-taxol sua utilizacao anti-neoplasica e composicoes farmaceuticas que os contem
AR011106A1 (es) COMPOSICIoN FARMACÉUTICA PARA EL TRAMIENTO O PREVENCI.ON DE LA DIABETES MELLITUS TIPO 2,
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
AR002949A1 (es) Análogos del peptido p277 y composiciónes farmaceuticas y preparaciónes que los comprenden para el tratamiento o diagnostico de diabetes y un equipo para diagnosticar.
DK0888323T3 (da) Dihydrobenzofuran og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
BR0213181A (pt) Combinações de inibidor de cox-2
DE69101833D1 (de) Harzzusammensetzung für ultravioleten lumineszenten Schirm.
CL2004000219A1 (es) Compuestos derivados de 2-iminotiazolidina; composicion farmaceutica que lo comprende; un proceso para la preparacion de dicha composicion; y su uso para el tratamiento de la obesidad.
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
PT952975E (pt) Compostos bi-aromaticos ligados por um radical hetero-etinileno e composicoes farmaceuticas e cosmeticas que os contem
CO4940457A1 (es) Composiciones farmaceuticas que comprenden sensibilizadores a insulina para tratamiento de la diabetes
UY25103A1 (es) Composición para el tratamiento de diabetes mellitus
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
CL2004001291A1 (es) Composicion farmaceutica que comprende compuestos carbociclicos y heterociclicos; y su uso para el tratamiento o profilaxis de la infeccion por influenza.
ES2187666T3 (es) Nicorandil para la neurosis de ansiedad.
ES2049711T3 (es) Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de cistinuria.